120 related articles for article (PubMed ID: 11857074)
1. The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Oncogene; 2002 Feb; 21(9):1309-15. PubMed ID: 11857074
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional control of fetal liver hematopoiesis: dominant negative effect of the overexpression of the LIM domain mutants of LMO2.
Terano T; Zhong Y; Toyokuni S; Hiai H; Yamada Y
Exp Hematol; 2005 Jun; 33(6):641-51. PubMed ID: 15911088
[TBL] [Abstract][Full Text] [Related]
3. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis.
Amoh Y; Yang M; Li L; Reynoso J; Bouvet M; Moossa AR; Katsuoka K; Hoffman RM
Cancer Res; 2005 Jun; 65(12):5352-7. PubMed ID: 15958583
[TBL] [Abstract][Full Text] [Related]
4. The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice.
Yamada Y; Pannell R; Forster A; Rabbitts TH
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):320-4. PubMed ID: 10618416
[TBL] [Abstract][Full Text] [Related]
5. Identification of the key LMO2-binding determinants on Ldb1.
Ryan DP; Sunde M; Kwan AH; Marianayagam NJ; Nancarrow AL; Vanden Hoven RN; Thompson LS; Baca M; Mackay JP; Visvader JE; Matthews JM
J Mol Biol; 2006 May; 359(1):66-75. PubMed ID: 16616188
[TBL] [Abstract][Full Text] [Related]
6. The Lim-only protein LMO2 acts as a positive regulator of erythroid differentiation.
Hansson A; Zetterblad J; van Duren C; Axelson H; Jönsson JI
Biochem Biophys Res Commun; 2007 Dec; 364(3):675-81. PubMed ID: 17964543
[TBL] [Abstract][Full Text] [Related]
7. Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
Shojaei F; Wu X; Zhong C; Yu L; Liang XH; Yao J; Blanchard D; Bais C; Peale FV; van Bruggen N; Ho C; Ross J; Tan M; Carano RA; Meng YG; Ferrara N
Nature; 2007 Dec; 450(7171):825-31. PubMed ID: 18064003
[TBL] [Abstract][Full Text] [Related]
8. The significance of LMO2 expression in the progression of prostate cancer.
Ma S; Guan XY; Beh PS; Wong KY; Chan YP; Yuen HF; Vielkind J; Chan KW
J Pathol; 2007 Feb; 211(3):278-85. PubMed ID: 17167821
[TBL] [Abstract][Full Text] [Related]
9. Of mice and men: how an oncogene transgresses the limits and predisposes to T cell acute lymphoblastic leukemia.
Hoang T
Sci Transl Med; 2010 Mar; 2(21):21ps10. PubMed ID: 20374994
[TBL] [Abstract][Full Text] [Related]
10. A postulated role for transcriptional regulator LMO2 in the proliferation and involution of hemangioma.
Sun ZJ; Zhang L; Zhao YF
Med Hypotheses; 2006; 67(5):1230-2. PubMed ID: 16793212
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the lmo2 promoter during hematopoietic and vascular development in zebrafish.
Zhu H; Traver D; Davidson AJ; Dibiase A; Thisse C; Thisse B; Nimer S; Zon LI
Dev Biol; 2005 May; 281(2):256-69. PubMed ID: 15893977
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic T cell LIM-protein Lmo2 forms part of a DNA-binding complex specifically in immature T cells.
Grütz GG; Bucher K; Lavenir I; Larson T; Larson R; Rabbitts TH
EMBO J; 1998 Aug; 17(16):4594-605. PubMed ID: 9707419
[TBL] [Abstract][Full Text] [Related]
13. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12.
Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM
Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069
[TBL] [Abstract][Full Text] [Related]
14. LMO2 promotes angiogenesis probably by up-regulation of bFGF in endothelial cells: an implication of its pathophysiological role in infantile haemangioma.
Sun ZJ; Cai Y; Chen G; Wang R; Jia J; Chen XM; Zheng LW; Zhao YF
Histopathology; 2010 Oct; 57(4):622-32. PubMed ID: 20955387
[TBL] [Abstract][Full Text] [Related]
15. The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis.
Chung GT; Yamada Y; Pannell R; Forster A; Rabbitts TH
Nucleic Acids Res; 2003 Apr; 31(8):e46. PubMed ID: 12682381
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
17. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
18. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
Goto H; Yano S; Zhang H; Matsumori Y; Ogawa H; Blakey DC; Sone S
Cancer Res; 2002 Jul; 62(13):3711-5. PubMed ID: 12097279
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of angiogenesis by Abeta peptides.
Paris D; Townsend K; Quadros A; Humphrey J; Sun J; Brem S; Wotoczek-Obadia M; DelleDonne A; Patel N; Obregon DF; Crescentini R; Abdullah L; Coppola D; Rojiani AM; Crawford F; Sebti SM; Mullan M
Angiogenesis; 2004; 7(1):75-85. PubMed ID: 15302999
[TBL] [Abstract][Full Text] [Related]
20. Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth.
Fahmy RG; Dass CR; Sun LQ; Chesterman CN; Khachigian LM
Nat Med; 2003 Aug; 9(8):1026-32. PubMed ID: 12872165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
